Davis Sarah E, Hynan Linda S, Limbers Christine A, Andersen C Mariam, Greene Medrith C, Varni James W, Iannaccone Susan T
Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390-9063, USA.
J Clin Neuromuscul Dis. 2010 Mar;11(3):97-109. doi: 10.1097/CND.0b013e3181c5053b.
To evaluate the reliability and validity of the PedsQL 3.0 Neuromuscular Module (NMM) in assessing health-related quality of life in the Duchenne muscular dystrophy (DMD) population for use as a secondary outcome measure in phase III clinical trials.
DMD is the most common genetic form of muscular dystrophy in childhood. Clinical trials are underway to evaluate modalities of treatment. The NMM was developed based on interviews of patients with DMD and spinal muscular atrophy. To determine the PedsQL reliability and validity, we administered the NMM to patients with DMD and their caregivers.
DESIGN/METHODS: Boys 8 to 18 years old with DMD were recruited from a neuromuscular disease clinic. At baseline, the child and caregiver completed the NMM and the PedsQL 4.0 Generic Core Scales (GC). The NMM was repeated 2 to 6 weeks later. Reliability was assessed using Cronbach's coefficient alpha (internal consistency) and intraclass correlation (ICC) (test-retest consistency). Construct validity was assessed by comparing baseline child and caregiver NMM total scores with the GC Total Score, forced vital capacity, cardiac ejection fraction, and ambulatory status.
Forty-four children and their caregivers completed the study. Internal consistency reliability of the total scale score of the NMM was demonstrated (Child alpha = 0.85; Caregiver alpha = 0.87). Test-retest reliability of the NMM was also demonstrated (Child ICC = 0.75, P = 0.001; Caregiver ICC = 0.85, P < 0.001). Validity of the total scale score of the NMM when compared with the GC Total Scale Score was supported (Child r (41) = 0.63, P < 0.001; Caregiver r (42) = 0.64, P < 0.001). Validity of the NMM compared with forced vital capacity was also supported (Child r (38) = 0.35, P = 0.032; Caregiver r (39) = 0.41, P = 0.01). The NMM parent-proxy-report and child self-report "About My Child's Neuromuscular Disease" scale was significantly related to wheelchair use (P < 0.008 and 0.016, respectively); the GC "Child Self-Report "Physical Health" scale was also significantly related to wheelchair use (P < 0.001). We were unable to conduct any analysis with ejection fraction because of the small number of children across all categories.
The PedsQL NMM is a reliable measure of disease-specific health-related quality of life in the DMD population and may be used as an outcome measure in clinical trials.
评估儿童生活质量量表3.0神经肌肉模块(NMM)在评估杜氏肌营养不良症(DMD)患者健康相关生活质量方面的可靠性和有效性,以用作III期临床试验的次要结局指标。
DMD是儿童期最常见的遗传性肌营养不良症。正在进行临床试验以评估治疗方式。NMM是基于对DMD和脊髓性肌萎缩症患者的访谈而开发的。为了确定儿童生活质量量表的可靠性和有效性,我们对DMD患者及其照料者进行了NMM测试。
设计/方法:从神经肌肉疾病诊所招募8至18岁的DMD男孩。在基线时,儿童及其照料者完成了NMM和儿童生活质量量表4.0通用核心量表(GC)。2至6周后重复进行NMM测试。使用克朗巴哈系数α(内部一致性)和组内相关系数(ICC)(重测一致性)评估可靠性。通过比较儿童和照料者基线时NMM总分与GC总分、用力肺活量、心脏射血分数和步行状态来评估结构效度。
44名儿童及其照料者完成了研究。证明了NMM总量表得分的内部一致性可靠性(儿童α=0.85;照料者α=0.87)。也证明了NMM的重测可靠性(儿童ICC=0.75,P=0.001;照料者ICC=0.85,P<0.001)。支持NMM总量表得分与GC总量表得分相比的效度(儿童r(41)=0.63,P<0.001;照料者r(42)=0.64,P<0.001)。也支持NMM与用力肺活量相比的效度(儿童r(38)=0.35,P=0.032;照料者r(39)=0.41,P=0.01)。NMM家长代理报告和儿童自我报告“关于我孩子的神经肌肉疾病”量表与轮椅使用显著相关(分别为P<0.008和0.016);GC“儿童自我报告”身体健康“量表也与轮椅使用显著相关(P<0.001)。由于所有类别中的儿童数量较少,我们无法对射血分数进行任何分析。
儿童生活质量量表NMM是评估DMD患者疾病特异性健康相关生活质量的可靠指标,可作为临床试验的结局指标。